Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma

SIMPLE SUMMARY: PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab) are widely used in metastatic melanoma, and most immune-related adverse events are known. Recently, several cardiovascular AEs (CVAEs, i.e., myocardial infarction, heart failure, stroke, Takotsubo syndrom...

Descripción completa

Detalles Bibliográficos
Autores principales: L’Orphelin, Jean-Matthieu, Dollalille, Charles, Akroun, Julia, Alexandre, Joachim, Dompmartin, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093552/
https://www.ncbi.nlm.nih.gov/pubmed/37046831
http://dx.doi.org/10.3390/cancers15072170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093552/
https://www.ncbi.nlm.nih.gov/pubmed/37046831
http://dx.doi.org/10.3390/cancers15072170

Ejemplares similares